These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 12089569)

  • 1. The rise of the European bioentrepreneur.
    Alper J
    Nat Biotechnol; 2002 Jul; 20 Suppl():BE3-5. PubMed ID: 12089569
    [No Abstract]   [Full Text] [Related]  

  • 2. The rise of European venture capital for biotechnology.
    Howell M; Trull M; Dibner MD
    Nat Biotechnol; 2003 Nov; 21(11):1287-91. PubMed ID: 14595356
    [No Abstract]   [Full Text] [Related]  

  • 3. Mixed results in Q1.
    Lawrence S
    Nat Biotechnol; 2005 May; 23(5):518. PubMed ID: 15877059
    [No Abstract]   [Full Text] [Related]  

  • 4. 2006: a stellar year for financing.
    Lawrence S
    Nat Biotechnol; 2007 Feb; 25(2):156. PubMed ID: 17287738
    [No Abstract]   [Full Text] [Related]  

  • 5. VC funding hits high in Q1.
    Lawrence S
    Nat Biotechnol; 2007 May; 25(5):496. PubMed ID: 17483825
    [No Abstract]   [Full Text] [Related]  

  • 6. Enthusiasm cools in Q2.
    Lawrence S
    Nat Biotechnol; 2005 Aug; 23(8):914. PubMed ID: 16082352
    [No Abstract]   [Full Text] [Related]  

  • 7. US venture capital for biotechnology.
    Dibner MD; Trull M; Howell M
    Nat Biotechnol; 2003 Jun; 21(6):613-7. PubMed ID: 12776144
    [No Abstract]   [Full Text] [Related]  

  • 8. Looking at US versus European exit opportunities.
    Lawrence S
    Nat Biotechnol; 2005 Oct; 23(10):1203. PubMed ID: 16302294
    [No Abstract]   [Full Text] [Related]  

  • 9. The German MedTech industry in 2007.
    Schmitt JM; Beeres M
    Med Device Technol; 2007; 18(7):56. PubMed ID: 18075138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Divining the path to a successful European exit.
    Buch HK; Gustafsson AC; Drvota V; Sundberg CJ
    Nat Biotechnol; 2011 Mar; 29(3):205-7. PubMed ID: 21510008
    [No Abstract]   [Full Text] [Related]  

  • 11. IPOs break $1 billion in Q2.
    Lawrence S
    Nat Biotechnol; 2007 Aug; 25(8):833. PubMed ID: 17687349
    [No Abstract]   [Full Text] [Related]  

  • 12. Nurturing the business of biotechnology.
    Nat Biotechnol; 2002 Jul; 20 Suppl():BE1. PubMed ID: 12089568
    [No Abstract]   [Full Text] [Related]  

  • 13. Boutiques reborn in 2003.
    Surendran A
    Nat Biotechnol; 2004 Mar; 22(3):353-4. PubMed ID: 15017987
    [No Abstract]   [Full Text] [Related]  

  • 14. Biotech holds its own in Q2.
    Lawrence S
    Nat Biotechnol; 2004 Aug; 22(8):938. PubMed ID: 15286634
    [No Abstract]   [Full Text] [Related]  

  • 15. Tech transfer fails to translate into startups.
    Lawrence S
    Nat Biotechnol; 2007 Jun; 25(6):616. PubMed ID: 17557089
    [No Abstract]   [Full Text] [Related]  

  • 16. Survey reveals US university licensing up, startup formation down.
    Bouchie A
    Nat Biotechnol; 2005 Feb; 23(2):261-2. PubMed ID: 15724274
    [No Abstract]   [Full Text] [Related]  

  • 17. The industry in Europe: more together than apart.
    Med Device Technol; 2005 Nov; 16(9):32, 34, 36-7. PubMed ID: 16438447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biotech IPOs--flop or pop?
    Jacobs T
    Nat Biotechnol; 2004 Aug; 22(8):949. PubMed ID: 15286641
    [No Abstract]   [Full Text] [Related]  

  • 19. Mind the (biomedical funding) gap.
    Klausner A
    Nat Biotechnol; 2005 Oct; 23(10):1217-8. PubMed ID: 16211055
    [No Abstract]   [Full Text] [Related]  

  • 20. The changing attitude of European VCs.
    Mitchell P
    Nat Biotechnol; 2004 Apr; 22(4):479. PubMed ID: 15085807
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.